Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 12, 2017 16:01 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

SOUTH SAN FRANCISCO, Calif., April 12, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
April 11, 2017 08:01 ET | Source: Catalyst Biosciences, Inc.

Key Milestone Reached in Catalyst’s Subcutaneous Factor IX Program

-- Milestone payment received with completion of IND-enabling toxicology studies -- -- Catalyst’s collaborator, ISU Abxis, plans to initiate a Phase 1/2 proof-of-concept study in individuals...
April 07, 2017 08:30 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
March 30, 2017 16:59 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Emergence from Key Patent Opposition Period Supporting Marzeptacog Alfa (activated), Catalyst’s Lead Clinical Program

-- European Patent Office indicates that no opposition to Catalyst’s patent has been filed ---- INC Research selected as CRO for Phase 2/3 efficacy clinical trial of Factor VIIa, marzeptacog alfa...
March 28, 2017 08:01 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program

-- Investigational New Drug (IND) approval from Korean Ministry of Food and Drug Safety represents a key milestone in Catalyst’s Factor IX development program -- -- Catalyst’s collaborator, ISU...
March 08, 2017 08:01 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

- Phase 1/2 Proof-of-Concept Clinical Trial of High Potency Factor IX CB 2679d/ISU304 in Individuals with Hemophilia B to Commence in the Second Quarter of 2017 - - Phase 2 Part of a Phase 2/3...
February 16, 2017 08:01 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Promotion of Andrew Hetherington to SVP of Technical Operations

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (Nasdaq:CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
February 14, 2017 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor Conference

-- Planned 2017 Initiation of Hemophilia B Clinical Trials Supported by Results from Preclinical Subcutaneous Dosing Studies of Next-Generation Coagulation Factors -- SOUTH SAN FRANCISCO, Calif.,...
February 10, 2017 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces 1-for-15 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
February 03, 2017 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at 19th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...